Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BMS selects Isis compound for cardiovascular disease treatment
May 2008
SHARING OPTIONS:

NEW YORK—Bristol-Myers Squibb Co. has selected a compound from its collaboration with Isis Pharmaceuticals as a development candidate for the treatment of cardiovascular disease. In May 2007, the two companies entered into a collaboration agreement to identify antisense drugs that target proprotein convertase subtilisin kexin 9 (PCSK9). The development candidate is an antisense inhibitor of PCSK9 that helps regulate the amount of cholesterol in the bloodstream.

Now that the first milestone in the collaboration has been achieved, Isis will receive a $2 million payment.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.